Navigation Links
New molecular insight into amboebic dysentery
Date:6/14/2008

In the June 15th issue of G&D, Dr. Sinisa Urban (Johns Hopkins University School of Medicine) and colleagues reveal a potential role for the rhomboid enzyme, EhROM1, in the pathogenesis of the enteric protozoan parasite, E. histolytica. This discovery posits EhROM1 as a prospective target in the treatment of amoebic dysentery, which affects 1/10th of the global population (~500 million people) and represents the second most common disease in the world.

"New drug targets are needed for amebiasis as current treatments have associated toxicities and drug resistance is a concern." said Dr. Upinder Singh, a clinician at Stanford University and co-author of the study.

E. histolytica is a single-celled intestinal parasite that infects the lower GI tract, causing amoebiasis, and can invade the intestinal wall and spread to the bloodstream, causing potentially fatal amoebic liver abscesses. The parasite is transmitted through fecally contaminated food or water, and is a major public health threat in the developing world.

Dr. Urban and colleagues uncovered new insight into the activity of E. histolytica's single rhomboid protease protein, EhROM1, which suggests that it helps the parasite evade the host's immune response. In order to escape immune detection, E. histolytica trophozoites concentrate immune system-eliciting surface proteins towards the rear of the cell and then expel them. Dr. Urban's team discovered that EhROM1 processes surface lectin proteins, and collaborators at Stanford University found that it re-localizes posteriorly during lectin shedding.

These findings suggest that EhROM1 facilitates lectin shedding and host immune system evasion by this pathogenic parasite. Dr. Urban is excited by the new findings, since "Enzymes have served as particularly successful drug targets in the past, so it's exciting to discover an ameba rhomboid enzyme with similar properties as a malaria rhomboid. We're hopeful that with addition
'/>"/>

Contact: Heather Cosel-Pieper
coselpie@cshl.edu
Cold Spring Harbor Laboratory
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. Molecular insight begins Trofex Phase 1 trial for detection of metastatic prostate cancer
2. Molecular insight begins Trofex Ph. 1 trial for detection of metastatic prostate cancer
3. Siemens Showcases Innovative Leadership in Molecular Imaging at SNM 2008
4. Xceed Molecular Licenses Signature from Moffitt Cancer Center and Adds Moffitt to Strategic Collaborator Program
5. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
6. Research reveals molecular fingerprint of cocaine addiction
7. SNM hosts 55th Annual Meeting of Nuclear Medicine and Molecular Imaging Research
8. Study identifies molecular response of cartilage to injury
9. Molecular change may reveal risk of leukemia relapse
10. Study Details New Molecular Approach to Preventing Alzheimers
11. Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 2Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 3Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 4Health News:Journal of American College of Surgeons finds lung transplantation should be used in older patients 2Health News:Nurse practitioners don't realize how much their prescribing is being influenced by drug marketing 2Health News:Nurse practitioners don't realize how much their prescribing is being influenced by drug marketing 3Health News:Security Health Plan Becomes First ICSI Sponsor Outside of Minnesota 2Health News:Security Health Plan Becomes First ICSI Sponsor Outside of Minnesota 3Health News:Oh Baby, Interventional Radiology Makes Childbirth Safer 2Health News:Oh Baby, Interventional Radiology Makes Childbirth Safer 3Health News:Oh Baby, Interventional Radiology Makes Childbirth Safer 4Health News:Oh Baby, Interventional Radiology Makes Childbirth Safer 5Health News:Less Invasive Interventional Treatment Can Be Recommended as First-Line Treatment for 'Silent Killer,' Abdominal Aortic Aneurysm 2Health News:Less Invasive Interventional Treatment Can Be Recommended as First-Line Treatment for 'Silent Killer,' Abdominal Aortic Aneurysm 3Health News:Less Invasive Interventional Treatment Can Be Recommended as First-Line Treatment for 'Silent Killer,' Abdominal Aortic Aneurysm 4Health News:Less Invasive Interventional Treatment Can Be Recommended as First-Line Treatment for 'Silent Killer,' Abdominal Aortic Aneurysm 5
Breaking Medicine Technology:Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 2Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 3Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 4Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 5Veran Medical Receives FDA Clearance to Market Electromagnetic Navigated Bronchoscopy Product: The SPiN Drive(TM) System 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3FDA Announces Plans for LASIK Quality of Life Project 59587 1FDA Announces Plans for LASIK Quality of Life Project 59587 2FDA Announces Plans for LASIK Quality of Life Project 59587 3FDA Warns of Unapproved and Illegal H1N1 Drug Products Purchased Over the Internet 59582 1FDA Warns of Unapproved and Illegal H1N1 Drug Products Purchased Over the Internet 59582 2FDA Warns of Unapproved and Illegal H1N1 Drug Products Purchased Over the Internet 59582 3BioMed Realty Trust to Report 2009 Third Quarter Results 59577 1BioMed Realty Trust to Report 2009 Third Quarter Results 59577 2
Other Medicine Technology:New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 2New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 3New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 4New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 5New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 6New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 7New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 8New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 9New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 10New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 11New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 12New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 13New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 14QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy 2QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy 3